Efficacy of Topical Azithromycin versus Systemic Doxycycline in Treatment of Meibomian Gland Dysfunction
Table 4
Pain and discomfort, lid margin telangiectasia, conjunctivitis, frothy discharge, meniscus floaters and break-up time test in 2nd follow up between studied groups.
Topical azithromycin (n = 28)
Systemic doxycycline (n = 28)
value
Pain and discomfort
Mild
19 (67.86%)
17 (60.71%)
0.828
Moderate
7 (25.00%)
8 (28.57%)
Severe
2 (7.14%)
3 (10.71%)
Lid margin telangiectasia
0 & 1
13 (46.43%)
9 (32.14%)
0.452
2
11 (39.29%)
12 (42.86%)
3
4 (14.29%)
7 (25.00%)
Conjunctivitis
+ve
4 (14.29%)
11 (39.29%)
0.068
−ve
24 (85.71%)
17 (60.70%)
Frothy discharge
+ve
1 (3.57%)
3 (10.71%)
0.611
−ve
27 (96.43%)
25 (89.28%)
Meniscus floaters
+ve
5 (17.86%)
13 (46.43%)
0.044
−ve
23 (82.14%)
15 (53.57%)
Break-up time test (seconds)
9.11 ± 2.64
7.71 ± 1.98
0.029
6–14
5–11
Data are presented as mean ± SD, : significant as value ≤ 0.05.
